**Changes in Diagnosed Addiction Rates in Patients Prescribed OxyContin or Other Opioids after Introduction of Reformulated OxyContin**

Paul Coplan, Aditi Kadakia

Risk Management & Epidemiology, Purdue Pharma L.P., Stamford, CT

**BACKGROUND**

􀀀 Opioid analgesics are an important option for the treatment of moderate to severe chronic pain, but

their potential for abuse presents a significant risk

􀀀 OxyContin® (oxycodone HCl controlled release) is an extended-release (ER) oxycodone analgesic

that was reformulated in August 2010 with physicochemical barriers to breaking, crushing, or

dissolving, intended to deter abuse by injecting and snorting

􀀀 Post-marketing studies have reported reductions in abuse of reformulated OxyContin in substance

abuse treatment centers1, poison centers2,3, and abuser cohorts4, as well as reductions in overdose

fatalities5 and in doctor-shopping6

􀀀 This study assessed changes in the rates of diagnosed addiction/dependence among individuals

dispensed OxyContin or other opioid analgesics before and after introduction of reformulated

OxyContin

􀀀 The research done on validating ICD-9 codes for opioid abuse and addiction/dependence show that

these codes capture the intended events. Palmer, et al. in a study at Group Health Cooperative found

that 59.4% of patient who had ICD-9 codes for opioid abuse, addiction/ dependence diagnoses also

had diagnosed opioid abuse or addiction/dependence based on medical chart review.5 The number

could be higher than 59.4% if cases of addiction did not have this noted in their medical charts

**AIMS**

􀀀 We evaluated changes in the rates of diagnosed addiction among patients prescribed OxyContin after

its reformulation. Comparator opioids were used to distinguish OxyContin-specific changes from

general opioid changes.

􀀀 The analysis focused on experience using a single opioid, rather than multiple opioids concomitantly,

so the effect of the single opioid could be studied without the influence of other opioids.

Presented at the College on Problems of Drug Dependence 77th Annual Scientific Meeting, Phoenix, AZ, June 13-18, 2015

**METHODS**

􀀀 **Study Design:** retrospective cohort study

􀀀 **Dataset:** MarketScan commercial database, August 2009-October 2013

􀀀 **Population**

• patients 18-64 years of age

• incident or prevalent users of OxyContin or 4 comparator opioids

• separate cohorts were included for each drug.

􀀀 **Study period:** divided in three times around introduction of reformulated OxyContin

• 1 year before (August 2009 – July 2010)

• 3 months transition period (August 2010 – October 2010)

• 3 years after (November 2010 – October 2013).

􀀀 **Opioid use:**

• Duration of continuous use defined by ≤15 days between prescriptions plus 15 days end of last

prescription

􀀀 **Person time of opioid use:**

• Addition of another opioid during an episode of continuous use of the primary opioid was taken into

consideration

• Person time was divided into two categories: opioid monotherapy and concomitant multiple opioid

use

• Person time in each category was summed for all individuals

• Person time accumulation began at the date of initial dispensing of opioid and ended at the

occurrence of an event or at the end of a dispensed medication use episode, whichever came first

􀀀 **Diagnosed event of interest:**

• Based on ICD-9 CM diagnostic codes of 304.0x and 304.7x codes

􀀀 **Classification of cases:**

• Cases classified by opioid based on medications used on day of diagnosed event or within 29

days prior to the event

􀀀 **Rates of diagnosed events:**

• Rates per 100 person years were calculated among patients prescribed OxyContin and

comparator opioids

• Change in rate one year before vs. three years after OxyContin reformulation assessed using

Poisson regression

• The 3-month transition period was excluded when calculating changes from the one year before to

the three years after reformulation

• Difference in change for comparator opioid groups versus OxyContin was calculated

**RESULTS**

􀀀 The rate of diagnosed addiction/dependence decreased 25% in the pre- versus post-reformulation

period among patients dispensed OxyContin (Figure 1)

􀀀 In contrast, the rate of diagnosed addiction/dependence among patients dispensed other opioids

changed by:

• ER morphine increased 21%

• ER oxymorphone increased 13%

• IR oxycodone SE increased 7%

• IR hydromorphone increased 31%

􀀀 The difference in change from baseline for OxyContin minus other comparator opioid groups was

significantly different (95% CI did not include) 0% change (Figure 2)

􀀀 The rates of diagnosed addiction per 100 person-years of opioid use were lower among patients

dispensed OxyContin (3 per 100 person-years of OxyContin monotherapy use) than the rates for the

four comparator opioids in the 3 years after reformulation (Figure 3)

􀀀 The number of diagnosed addiction/dependence cases decreased by 35% (from 481 to 315 per

year), while the person-time decreased by 13%, from 1 year before to 3 years after reformulation

(Table 1)

**Figure 1. Changes in Rates of Diagnosed Addiction/Dependence per 100 Person-Years**

**of Opioid Use in Individuals Dispensed One Opioid**

**Change from 1 year before to 3 years after introduction of reformulated OxyContin**

**Figure 2. Difference in Change from Baseline for OxyContin minus Other Opioid**

**Analgesics**

**Figure 3. Rates of Diagnosed Addiction/Dependence per 100 Person-Years of Opioid**

**Use in Individuals Dispensed One Opioid, 2011-2013**

**Table 1. Diagnosed Cases, Patients and Person Time for OxyContin and Comparator**

**Opioids before and after Reformulation of OxyContin**

**ADVANTAGES AND LIMITATIONS OF THE STUDY**

**Advantages**

􀀀 Focuses on patients dispensed opioid analgesics

􀀀 A validation study has shown that ICD-9 codes have good positive predictive value

􀀀 Very large sample size

􀀀 Geographically representative of the US

**Limitations**

􀀀 Does not capture Medicare and Medicaid patients

􀀀 Not all events are diagnosed

􀀀 ICD-9 codes assess opioid dependence, a euphemism for addiction, as defined by DSM-IV

􀀀 Not all diagnoses are accurate

􀀀 In patients using multiple opioids cannot identify which opioid associated with addiction

**PERSPECTIVE**

􀀀 Among individuals dispensed OxyContin without other opioids, rates of diagnosed

addiction/dependence per 100 person-years of opioid use decreased substantially from one year

before to three years after introduction of reformulated OxyContin

􀀀 In contrast, rates of diagnosed addiction/dependence increased among individuals dispensed other

opioid analgesics in the same time period

􀀀 The difference in change from baseline for OxyContin minus comparator opioids was significantly

different from 0%

􀀀 The results of this study indicate that diagnoses for opioid addiction/dependence decreased among

individuals prescribed OxyContin after its reformulation. It is not clear whether diagnoses decreased

because abusers stopped using OxyContin or pain patients using OxyContin were less likely to

become addicted, or a combination of both

􀀀 The findings from this study complement results from studies that assessed the effect of reformulated

OxyContin on abuse, misuse, or diversion to provide a more comprehensive assessment of the

introduction of reformulated OxyContin on public health

**CONCLUSIONS**

􀀀 Among individuals dispensed OxyContin without other opioids, rates of diagnosed

addiction/dependence per 100 person-years of opioid use decreased 25% from one year before to

three years after introduction of reformulated OxyContin

􀀀 The changes from one-year baseline among patients dispensed OxyContin were significantly different

from the changes from baseline for comparator opioid groups

􀀀 Abuse of OxyContin is still possible, including by oral use. Appropriately designed and evaluated

formulations appear able to improve addiction, however, residual addiction remains. Addiction is a

complex problem and a multi-dimensional approach is needed.

**REFERENCES**

1. Butler SF, Cassidy TA, Chilcoat H, Black RA, Landau C, Budman SH, Coplan PM. Abuse rates and routes of administration of reformulated extended-release

oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. ***J Pain.*** 2013;14(4):351-8.

2. Severtson SG, Bartelson BB, Davis JM, Muñoz A, Schneider MF, Chilcoat H, Coplan PM, Surratt H, Dart RC. Reduced abuse, therapeutic errors, and diversion

following reformulation of extended-release oxycodone in 2010. ***J Pain.*** 2013;14(10):1122-30.

3. Coplan PM, Kale H, Sandstrom L, Landau C, Chilcoat HD. changes in oxycodone and heroin exposures in the national poison data system after introduction of

extended-release oxycodone with abuse-deterrent characteristics. ***Pharmacoepidemiol Drug Saf.*** 2013;22(12):1274-1282.

4. Havens JR, Leukefeld CG, DeVeaugh-Geiss AM, Coplan P, Chilcoat HD. The impact of a reformulation of extended-release oxycodone designed to deter abuse is a

sample of prescription opioid abusers. ***Drug Alcohol Depend.*** 2014;139: 9-17.

5. Sessler NE, Downing JM, Kale H, Chilcoat HD, Baumgartner TF, Coplan PM Reductions in reported deaths following the introduction of extended-release

oxycodone (OxyContin) with an abuse-deterrent formulation. ***Pharmacoepidemiol Drug Saf.*** 2014;23(12): 1238-46.

6. Chilcoat H, Coplan P, Sessler N, Schultz B, Yuan Y. Impact of an opioid reformulation with abuse-deterrent properties on doctor-shopping. ***Journal of Pain.***

2014;15(4)Supplement1:S10 [Abstract #138] (Presented at the American Pain Society’s 33rd Annual Meeting Scientific Meeting, April 30-May 3, 2014, Tampa, FL)

7. Palmer R, Carrell DS, Cronkite D, Saunders K, Gross DE, Masters E, Donevan S, Hylan T, VonKorff M. The Prevalence of Problem Opioid Use in Patients

Receiving Chronic Opioid Therapy: Computer Assisted Review of Electronic Health Record Clinical Notes. ***Pain.*** 2015;Mar

**Disclosure Statement**

􀀀 Research funded by Purdue Pharma L.P.

􀀀 All authors are employed by Purdue Pharma L.P.